CN1094347C - Release-controlled micropill for treating benign prostatic hyperplasis and its preparing process - Google Patents
Release-controlled micropill for treating benign prostatic hyperplasis and its preparing process Download PDFInfo
- Publication number
- CN1094347C CN1094347C CN99117214A CN99117214A CN1094347C CN 1094347 C CN1094347 C CN 1094347C CN 99117214 A CN99117214 A CN 99117214A CN 99117214 A CN99117214 A CN 99117214A CN 1094347 C CN1094347 C CN 1094347C
- Authority
- CN
- China
- Prior art keywords
- preparation
- controlled release
- gram
- suspension
- pastille
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a release control mini pill for curing benign prostate hyperplasia symptoms. The mini pill is prepared from epristeride, a blank pill core, ethyl cellulose, acrylic resin, a surface active agent, a plasticizing agent and a hydroxypropyl methyl cellulose antisticking agent. The present invention also discloses a preparation method for the release control mini pill. The release control mini pill of the present invention can effectively maintain more than 12 hours in an in vitro test. Compared with epristeride, the release control mini pill can properly control the release rate of the medicament and prolong the maintenance of the medicine blood effective concentration of the release control mini pill in the bodies of old people for improving a curative effect of the release control mini pill.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of benign prostatic hyperplasis and preparation method thereof, particularly a kind of controlled release micro pill for the treatment of benign prostatic hyperplasis and preparation method thereof.
Epristeride (Epristeride) (17 β-(the N-tert-butyl group-amino-formoxyl)-androstane-3; 5-diene-3-carboxylic acid) is a kind of 5-alpha-reductase inhibitors of uncompetitive; the treatment benign prostatic hyperplasis had good curative effect (Sun Zuyue, Tu Ceng Hong " pharmacy progress " 1995,19 (4) P211～215).But the result of study of the old human body single-dose of epristeride pharmacokinetics shows that the biological half-life of this medicine is t
1/2Therefore=5.095h can not keep this medicine for a long time in blood in human body in medicine valid density, influences the therapeutic effect of this medicine.
The object of the present invention is to provide a kind of micropill with treatment benign prostatic hyperplasis of control-release function, it can keep epristeride for a long time in old blood in human body in medicine valid density.
Another object of the present invention is to provide the preparation method of this controlled release micro pill.
Treatment benign prostatic hyperplasis controlled release micro pill of the present invention contains following component (following all be weight percentage): epristeride 2.5%～3.5% blank pill core 70.0%～82.5% ethyl cellulose 9.5%～17.5% acrylic resin 0.5%～1.0% surfactant 1.3%～2.5% plasticizer 2.2%～4.1% hydroxypropyl methylcellulose 0.5%～1.1% antiplastering aid 0.2%～0.4%
Above-mentioned each component is formed celphere, pastille confining bed, not pastille confining bed, controlled release clothing layer and seal-coat layer from inside to outside. wherein pastille confining bed is made up of following component: epristeride 85%～95% hydroxypropyl methylcellulose 4%～10% antiplastering aid 1%～5% not pastille confining bed is made up of following component: hydroxypropyl methylcellulose 60%～80% antiplastering aid 20%～40% controlled release clothing layer is made up of following component: ethyl cellulose 50%～90% acrylic resin 1%～8% surfactant 3%～16% plasticizer 6%～26% seal-coat layer is made up of following component: hydroxypropyl methylcellulose 55%～90% antiplastering aid 10%～45%
Wherein celphere is mixed by 30%～70% starch and 30%～70% sucrose, surfactant is a sodium lauryl sulphate, hexadecanol, monovalence ammonium soaps or their mixture, antiplastering aid is Pulvis Talci or Kaolin, plasticizer is a triethyl citrate, dibutyl sebacate, diethyl phthalate, the acetic acid monoglyceride, tributyl citrate, Oleum Ricini, triacetyl glycerine, cochin oil or oleic acid, the preferred enteric solubility I of acrylic resin acrylic resin latex, enteric solubility II acrylic resin, enteric solubility III acrylic resin, their structural formula is:
Wherein enteric solubility I acrylic resin latex is a methacrylic acid--butyl acrylate copolymer (polymer monomers n
1: n
2=1: 1, R
1Be H, R
2Be C
4H
9, M
w=2.5 * 10
5), enteric solubility II acrylic resin is methacrylic acid-methylmethacrylate copolymer (polymer monomers n
1: n
2=1: 1, R
1Be CH
3, R
2Be CH
3, M
w=1.35 * 10
5), enteric solubility III acrylic resin is methacrylic acid-methylmethacrylate copolymer (polymer monomers n
1: n
2=1: 2, R
1Be CH
3, R
2Be CH
3, M
w=1.35 * 10
5).
The preparation method of treatment benign prostatic hyperplasis controlled release micro pill of the present invention is made up of following steps: the preparation of (one) coating suspension successively
(1) preparation of suspension: 2～10 gram hydroxypropyl emthylcelluloses in 20～120ml80～90 ℃ distilled water immersion 2～8 hours, are added 0.2～10 gram antiplastering aid and 100～180ml95% ethanol then, stir, 200 mesh sieves filter.
(2) preparation of coating suspension: 2～6.5 gram epristerides are added 55～160ml95% dissolve with ethanol, add 6.0～47ml suspension again, stir.(2) preparation of controlled release coat liquid
13～65 gram ethyl celluloses, 1.3～3.3 gram acrylic resins, 3.8～17 gram plasticizers, 1.8～9.2 gram surfactants, 181～240ml distilled water are mixed, stir, filter with 200 mesh sieves.(3) preparation of pastille confining bed
After celphere 50～150 gram dryings, that 63～215ml coating suspension spray coating is in celphere, and then dry.(4) the not preparation of pastille confining bed
Continue spray coating, drying with 5～18ml suspension.(5) preparation of controlled release clothing layer
With 80～180ml controlled release coat liquid, continue spray coating, drying.(6) preparation of seal-coat layer
Continue spray coating, drying with 5～18ml suspension.
Wherein antiplastering aid has been crossed 200 mesh sieves, and spray coating carries out in ebullated bed coating machine, and the working condition of ebullated bed coating machine is 40～60 ℃ of baking temperatures, and atomisation pressure is 0.8～3.0bar, and the wriggling pump speed is 0.2～5ml/min.
The present invention treats the controlled release micro pill of benign prostatic hyperplasis and can effectively keep more than 12 hours in vitro tests, compare with epristeride, can suitably control the rate of release of medicament, can prolong this medicine, improve the therapeutic effect of this medicine the keeping of old blood in human body in medicine valid density.
The preparation of embodiment 1 (one) coating suspension
(1) preparation of suspension: 2 gram hydroxypropyl emthylcelluloses in 20ml80 ℃ of distilled water immersion 2 hours, are added 0.2 gram then and crossed 200 mesh sieve Pulvis Talci and 100ml95% ethanol, stir, 200 mesh sieves filter.
(2) preparation of coating suspension: 2 gram epristerides are added the 60ml95% dissolve with ethanol, add the 6.0ml suspension again, stir.(2) preparation of controlled release coat liquid
13 gram ethyl celluloses, 1.3 gram enteric solubility II acrylic resins, 3.8ml triethyl citrate, 1.8 gram sodium lauryl sulphates, 181ml distilled water are mixed, stir, filter with 200 mesh sieves.(3) preparation of pastille confining bed
After 50 ℃ of following dryings of celphere that 50% starch and 50% sucrose mix, 50 grams, that 63ml coating suspension spray coating is in celphere, and then dry.(4) the not preparation of pastille confining bed
Continue spray coating, drying with the 5ml suspension.(5) preparation of controlled release clothing layer
With 80ml controlled release coat liquid, continue spray coating, drying.(6) preparation of seal-coat layer
Continue spray coating, drying with the 5ml suspension.Promptly get white spherical piller, treat the controlled release micro pill of benign prostatic hyperplasis for the present invention.
The preparation of embodiment 2 (one) coating suspensions
(1) preparation of suspension: 5 gram hydroxypropyl emthylcelluloses in 60ml85 ℃ of distilled water immersion 4 hours, are added 2 grams then and crossed 200 mesh sieve Kaolin and 140ml95% ethanol, stir, 200 mesh sieves filter.
(2) preparation of coating suspension: 3.5 gram epristerides are added the 100ml95% dissolve with ethanol, add the 11ml suspension again, stir.(2) preparation of controlled release coat liquid
36.5 ethyl celluloses, 1.9 gram enteric solubility III acrylic resins, 9 gram dibutyl sebacates, 5.5 gram hexadecanol, 212ml distilled water are mixed, stir, filter with 200 mesh sieves.(3) preparation of pastille confining bed
After 50 ℃ of following dryings of celphere that 30% starch and 70% sucrose mix, 90 grams, that 114ml coating suspension spray coating is in celphere, and then dry.(4) the not preparation of pastille confining bed
Continue spray coating, drying with the 10ml suspension.(5) preparation of controlled release clothing layer
With 120ml controlled release coat liquid, continue spray coating, drying.(6) preparation of seal-coat layer
Continue spray coating, drying with the 13ml suspension.Promptly get white spherical piller, treat the controlled release micro pill of benign prostatic hyperplasis for the present invention.
The preparation of embodiment 3 (one) coating suspensions
(1) preparation of suspension: 10 gram hydroxypropyl emthylcelluloses in 120ml90 ℃ of distilled water immersion 8 hours, are added 10 grams then and crossed 200 mesh sieve Pulvis Talci and 180ml95% ethanol, stir, 200 mesh sieves filter.
(2) preparation of coating suspension: 8 gram epristerides are added the 160ml95% dissolve with ethanol, add the 47ml suspension again, stir.(2) preparation of controlled release coat liquid
Eudragit L30 D-55 acrylic resin, 17 gram triacetyl glycerines, 2 gram hexadecanol, 3 gram ammonium alginates, the 240ml distilled water of 65 ethyl celluloses, 3.3 gram Shanghai Romo Co.,Ltd are mixed, stir, filter with 200 mesh sieves.(3) preparation of pastille confining bed
After 50 ℃ of following dryings of celphere that 70% starch and 30% sucrose mix, 150 grams, that 200ml coating suspension spray coating is in celphere, and then dry.(4) the not preparation of pastille confining bed
Continue spray coating, drying with the 18ml suspension.(5) preparation of controlled release clothing layer
With 180ml controlled release coat liquid, continue spray coating, drying.(6) preparation of seal-coat layer
Continue spray coating, drying with the 18ml suspension.Promptly get white spherical piller, treat the controlled release micro pill of benign prostatic hyperplasis for the present invention.
The test of embodiment 4 releases
Get embodiment 1,2, the controlled release micro pill that makes in 3, be numbered sample 1, sample 2, sample 3, according to drug release determination method (two appendix XD first methods of Chinese Pharmacopoeia nineteen ninety-five version), adopt dissolution method second subtraction unit, 800ml is a solvent with sodium hydroxide solution (0.001mol/L), rotating speed is that per minute 80 changes, operation in accordance with the law, through 1,2, in the time of 4 and 8 hours, get solution 10ml respectively, and replenish uniform temp simultaneously, the sodium hydroxide solution of equal volume (0.001mol/L), filter, get subsequent filtrate,, measure trap at the wavelength place of 266nm according to spectrophotography (the 18th page of two appendix IVA of Chinese Pharmacopoeia nineteen ninety-five version); Other gets epristeride 15mg, puts in the 100ml volumetric flask, and the about 60ml of hydro-oxidation sodium solution (0.001mol/L) ultrasonicly makes whole dissolvings, is cooled to room temperature, and (0.001mol/L) is diluted to scale with sodium hydroxide solution, shakes up, and filters; Precision is measured subsequent filtrate 2ml, puts in the 50ml volumetric flask, and (0.001mol/L) is diluted to scale with sodium hydroxide solution, shakes up, and measures with method.Measurement result is as shown in table 1.
Table 1 controlled release micro pill release test of the present invention
| Sample time (hour) | Average accumulated discharges percentage ratio (%) | |
| 1 2 4 8 | Sample number into spectrum | 1 2 3 |
| 19.29 17.13 16.73 30.50 30.69 28.27 53.98 52.36 51.98 83.30 83.59 82.80 | ||
Claims (10)
1, a kind of controlled release micro pill for the treatment of benign prostatic hyperplasis, contain following component (following all be weight percentage): epristeride 2.5%～3.5% celphere 70.0%～82.5% ethyl cellulose 9.5%～17.5% acrylic resin 0.5%～1.0% surfactant 1.3%～2.5% plasticizer 2.2%～4.1% hydroxypropyl emthylcellulose 0.5%～1.1% antiplastering aid 0.2%～0.4% wherein each component is formed celphere from inside to outside, the pastille confining bed, pastille confining bed not, controlled release clothing layer and seal-coat layer, the pastille confining bed is made up of following component: epristeride 85%～95% hydroxypropyl emthylcellulose 4%～10% antiplastering aid 1%～5% not pastille confining bed is made up of following component: hydroxypropyl emthylcellulose 60%～80% antiplastering aid 20%～40% controlled release clothing layer is made up of following component: ethyl cellulose 50%～90% acrylic resin 1%～8% surfactant 3%～16% plasticizer 6%～26% seal-coat layer is made up of following component: hydroxypropyl emthylcellulose 55%～90% antiplastering aid 10%～45%
2, controlled release micro pill as claimed in claim 1 is characterized in that celphere is mixed by 30%～70% starch and 30%～70% sucrose.
3, controlled release micro pill as claimed in claim 1 is characterized in that the preferred enteric solubility I of acrylic resin acrylic resin latex, enteric solubility II acrylic resin, enteric solubility III acrylic resin.
4, controlled release micro pill as claimed in claim 1 is characterized in that surfactant is sodium lauryl sulphate, hexadecanol, monovalence ammonium soaps or their mixture.
5, controlled release micro pill as claimed in claim 1 is characterized in that antiplastering aid is Pulvis Talci or Kaolin.
6, controlled release micro pill as claimed in claim 1 is characterized in that plasticizer is triethyl citrate, dibutyl sebacate, diethyl phthalate, acetic acid monoglyceride, tributyl citrate, Oleum Ricini, triacetyl glycerine, cochin oil or oleic acid.
7, a kind of method for preparing the described controlled release micro pill of claim 1 is made up of following steps: the preparation of (one) coating suspension successively
(1) preparation of suspension: 2～10 gram hydroxypropyl emthylcelluloses in 20～120ml80～90 ℃ distilled water immersion 2～8 hours, are added 0.2～10 gram antiplastering aid and 100～180ml95% ethanol then, stir, 200 mesh sieves filter.
(2) preparation of coating suspension: 2～6.5 gram epristerides are added 55～160ml95% dissolve with ethanol, add 6.0～47ml suspension again, stir.(2) preparation of controlled release coat liquid
13～65 gram ethyl celluloses, 1.3～3.3 gram acrylic resins, 3.8～17 gram plasticizers, 1.8～9.2 gram surfactants, 181～240ml distilled water are mixed, stir, filter with 200 mesh sieves.(3) preparation of pastille confining bed
After celphere 50～150 gram dryings, that 63～215ml coating suspension spray coating is in celphere, and then dry.(4) the not preparation of pastille confining bed
Continue spray coating, drying with 5～18ml suspension.(5) preparation of controlled release clothing layer
With 80～180ml controlled release coat liquid, continue spray coating, drying.(6) preparation of seal-coat layer
Continue spray coating, drying with 5～18ml suspension.
8, preparation method as claimed in claim 7 is characterized in that antiplastering aid 200 mesh sieves excessively.
9, preparation method as claimed in claim 7 is characterized in that spray coating carries out in ebullated bed coating machine.
10, preparation method as claimed in claim 7, the working condition that it is characterized in that ebullated bed coating machine are 40～60 ℃ of baking temperatures, and atomisation pressure is 0.8～3.0bar, and the wriggling pump speed is 0.2～5ml/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99117214A CN1094347C (en) | 1999-11-15 | 1999-11-15 | Release-controlled micropill for treating benign prostatic hyperplasis and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99117214A CN1094347C (en) | 1999-11-15 | 1999-11-15 | Release-controlled micropill for treating benign prostatic hyperplasis and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1255332A CN1255332A (en) | 2000-06-07 |
| CN1094347C true CN1094347C (en) | 2002-11-20 |
Family
ID=5279854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99117214A Expired - Fee Related CN1094347C (en) | 1999-11-15 | 1999-11-15 | Release-controlled micropill for treating benign prostatic hyperplasis and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1094347C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100421666C (en) * | 2006-07-27 | 2008-10-01 | 江苏联环药业股份有限公司 | Epristeride slow release preparation |
| CN101602865B (en) * | 2009-03-13 | 2011-08-31 | 王懋 | Ethylcellulose mixed suspension liquid and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1200924A (en) * | 1997-05-29 | 1998-12-09 | 伊莱利利公司 | Fluoxetine enteric micropills |
| CN1213301A (en) * | 1996-03-15 | 1999-04-07 | 日研化学株式会社 | Sustained-release metal valproate tablets |
-
1999
- 1999-11-15 CN CN99117214A patent/CN1094347C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1213301A (en) * | 1996-03-15 | 1999-04-07 | 日研化学株式会社 | Sustained-release metal valproate tablets |
| CN1200924A (en) * | 1997-05-29 | 1998-12-09 | 伊莱利利公司 | Fluoxetine enteric micropills |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100421666C (en) * | 2006-07-27 | 2008-10-01 | 江苏联环药业股份有限公司 | Epristeride slow release preparation |
| CN101602865B (en) * | 2009-03-13 | 2011-08-31 | 王懋 | Ethylcellulose mixed suspension liquid and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1255332A (en) | 2000-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2653403C (en) | Lipoic acid pellets | |
| RU2375047C2 (en) | Pharmaceutical medicinal form, resistant to gastric juice activity, which includes n-(2-(2-phthalimidoetoxy)acetyl)-l-alanyl-d-glutamic acid (lk 423) | |
| IE60313B1 (en) | Sustained release pharmaceutical composition | |
| CN1094347C (en) | Release-controlled micropill for treating benign prostatic hyperplasis and its preparing process | |
| CN1161112C (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
| CA3160876A1 (en) | Dosage form comprising an alkaline agent and an enteric coating layer | |
| US20100256088A1 (en) | Low dose therapy for treating viral infections | |
| CN1126534C (en) | Intracoronary stent containing quinazolinone derivative | |
| CN114681392A (en) | Sustained-release oral solid composition | |
| CN101721375B (en) | Insulin slow release micron sphere composition and preparation method thereof | |
| CN102552165B (en) | Sarpogrelate hydrochloride sustained release pellet and preparation method thereof | |
| CN103211786A (en) | Choline fenofibrate film-controlled enteric slow-release pellet capsule | |
| Tan et al. | Degradable microneedle patch loaded with doxycycline hydrochloride and vascular endothelial growth factors for promoting diabetic wound healing | |
| KR101745750B1 (en) | Orally administrable pharmaceutical pellet of epidermal growth factor | |
| Parikh et al. | Oestrone loaded poly (l-lactic acid) microspheres: preparation, evaluation and in vitro release kinetics | |
| KR100542785B1 (en) | Experimental animals for evaluation of therapeutic effects on corneal epithelial damages | |
| CN101176724A (en) | Oxymatrine or matrine sustained-release pellet and preparation method thereof | |
| CN1634116A (en) | Stavudine sustained release tablet and its preparing process | |
| CN1883460A (en) | An enteric coated mini-pill of pantoprazole sodium | |
| CN1210022C (en) | Dichlofenac sodium slow-releasing preparation and its preparation method | |
| CN1839871A (en) | Azithromycin enteric coated microsphere and preparation method thereof | |
| CN111150831A (en) | Application of polypeptide Kdpt | |
| CN105726488A (en) | Enteric-coated pellet containing respiratory syncytial virus inhibitor and preparation method thereof | |
| CN112730278B (en) | Mathematical modeling method for slow release of tea polyphenol drug-loaded microsphere drug | |
| Ahmad et al. | Application of Psyllium, PEG, Agarose and Collagen Based Hydrogels for Controlled In Vitro and In Vivo Drug (Insulin) Delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |